SavvyMoney | $225,000,000 | (Oct 28, 2025)
Paygentic | $2,000,000 | (Oct 28, 2025)
Honey Health | $7,800,000 | (Oct 28, 2025)
Certified by Founder
Lodge
Vima Therapeutics
start up
United States
- Cambridge, Massachusetts
- 30/05/2025
- Series A
- $60,000,000
Vima Therapeutics is a clinical-stage biotechnology company pioneering a new era in the treatment of dystonia and related movement disorders.
We are advancing VIM0423, a potential first-in-class oral therapy for dystonia, with the goal of helping individuals regain control of their movements by targeting the underlying cause of the disease.
Vima brings together a team of physicians, scientists, and drug developers with deep expertise in movement disorders and a shared commitment to deliver a meaningful oral therapy for patients.
- Industry Biotechnology Research
- Website https://vimatx.com/
- LinkedIn https://www.linkedin.com/company/vima-therapeutics/
Natural | $9,800,000 | (Oct 28, 2025)
PodPlay Technologies | $8,000,000 | (Oct 28, 2025)
Seneca | $60,000,000 | (Oct 28, 2025)
Serval | $47,000,000 | (Oct 28, 2025)
Bridge(US) | $5,100,000 | (Oct 28, 2025)
Vermeer | $10,000,000 | (Oct 24, 2025)
GammaTime | $14,000,000 | (Oct 24, 2025)
Apriority Financial, Inc. | $2,300,000 | (Oct 24, 2025)
GradBridge | $20,000,000 | (Oct 24, 2025)